Compare Royal Bank of Canada (RY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Viatris Inc — how do they compare? Royal Bank of Canada trades at $210.37 (market cap $289.51B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Royal Bank of Canada is far larger — about 14.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| RY | VTRS | |
|---|---|---|
Market Cap | $289.51B | $19.79B |
Sector | Financials | Health |
52-Week High | $217.87 | $17.39 |
52-Week Low | $128.46 | $8.74 |
Dividend Yield | 2.42% | 2.83% |
Enterprise Value | — | $32.00B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
